Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications

Yu, Xinyu; Xu, Qingyu; Wu, Yuan; Jiang, Huijun; Wei, Wei; Zulipikaer, Azhati; Guo, Yan; Jirimutu,; Chen, Jin

doi:10.1039/d0bm00574f

Cited by 20 publications

(12 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…71 Recently, nanobodies have been speculated for application in COVID-19. 72 They are antigen-binding domains found in camelid species and are having only heavy chains, no light chains. They have compact structure, lower molecular weight, the smallest active antigen-binding fragments, better stability, and better penetration/bioavailability due to small size.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

“…They have compact structure, lower molecular weight, the smallest active antigen-binding fragments, better stability, and better penetration/bioavailability due to small size. 72 There are some limitations in monoclonal antibody based therapy including production limits, costs, and time involvement. 32 However, novel methods of production can overcome some of these limitations like expression systems in plants.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapies and immunomodulatory approaches in clinical trials - a mini review

Yatoo

Hamid

Rather

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created havoc worldwide. Due to the non-availability of any vaccine or drugs against COVID-19, immunotherapies involving convalescent plasma, immunoglobulins, antibodies (monoclonal or polyclonal), and the use of immunomodulatory agents to enhance immunity are valuable alternative options. Cell-based therapies including natural killer cells, T cells, stem cells along with cytokines and toll-like receptors (TLRs) based therapies are also being exploited potentially against COVID-19. Future research need to strengthen the field of developing effective immunotherapeutics and immunomodulators with a thrust of providing appropriate, affordable, convenient, and cost-effective prophylactic and treatment regimens to combat global COVID-19 crisis that has led to a state of medical emergency enforcing entire countries of the world to devote their research infrastructure and manpower in tackling this pandemic.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Immunotherapies and immunomodulatory approaches in clinical trials - a mini review

Yatoo

Hamid

Rather

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Adverse reactions to non-human antibodies are rare but they comport a safety risk for the patient, therefore it is pivotal to ensure that tracking antibodies have minimal pharmacological or toxicological effects. To minimize the risk of adverse reactions, antibodies of camelids, cartilaginous fish or human are often used ( 342 , 343 ). Camelid antibodies are significantly smaller than standard antibodies and only consist of IgG heavy chains ( 344 ).…”

Section: Clinically Applicable Detection Techniquesmentioning

confidence: 99%

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors

et al. 2021

View full text Add to dashboard Cite

In recent years, cancer immunotherapy experienced remarkable developments and it is nowadays considered a promising therapeutic frontier against many types of cancer, especially hematological malignancies. However, in most types of solid tumors, immunotherapy efficacy is modest, partly because of the limited accessibility of lymphocytes to the tumor core. This immune exclusion is mediated by a variety of physical, functional and dynamic barriers, which play a role in shaping the immune infiltrate in the tumor microenvironment. At present there is no unified and integrated understanding about the role played by different postulated models of immune exclusion in human solid tumors. Systematically mapping immune landscapes or “topographies” in cancers of different histology is of pivotal importance to characterize spatial and temporal distribution of lymphocytes in the tumor microenvironment, providing insights into mechanisms of immune exclusion. Spatially mapping immune cells also provides quantitative information, which could be informative in clinical settings, for example for the discovery of new biomarkers that could guide the design of patient-specific immunotherapies. In this review, we aim to summarize current standard and next generation approaches to define Cancer Immune Topographies based on published studies and propose future perspectives.

show abstract

“…Single domain antibody fragments often referred to as nanobodies, which is a trademark of Ablynx, are based on the variable domain of heavy chain-only camelid antibodies ( V HH ) (Hassanzadeh-Ghassabeh et al 2013 ; Jovcevska and Muyldermans 2020 ; Muyldermans 2020 ; Revets et al 2005 ; Vu et al 1997 ). These small protein domains of between 12 and 15 kDa are highly stable and easy to produce in large quantities, very soluble (Kim et al 2014 ; Rouet et al 2015 ; Salema and Fernandez 2013 ; Vu et al 1997 ) and are also easy to be modified with functional groups, protein adjuncts and fluorescent probes (Al-Baradie 2020 ; Carrington et al 2019 ; Jovcevska and Muyldermans 2020 ; Mortensen et al 2020 ; Wang et al 2019 ; Wu et al 2018 ; Yu et al 2020 ). The paratope of V HH sdAb’s consists of three variable complementarity determining regions (CDR) 1, 2 and 3 which convey ligand specificity and binding strength.…”

Section: Introductionmentioning

confidence: 99%

Interaction standards for biophysics: anti-lysozyme nanobodies

2021

View full text Add to dashboard Cite

There is a significant demand in the molecular biophysics community for robust standard samples. They are required by researchers, instrument developers and pharmaceutical companies for instrumental quality control, methodological development and in the design and validation of devices, diagnostics and instrumentation. To-date there has been no clear consensus on the need and type of standards that should be available and different research groups and instrument manufacturers use different standard systems which significantly hinders comparative analysis. One of the major objectives of the Association of Resources for Biophysical Research in Europe (ARBRE) is to establish a common set of standard samples that can be used throughout the biophysics community and instrument developers. A survey was circulated among ARBRE members to ascertain the requirements of laboratories when using standard systems and the results are documented in this article. In summary, the major requirements are protein samples which are cheap, relatively small, stable and have different binding strengths. We have developed a panel of sdAb’s or ‘nanobodies’ against hen-egg white lysozyme with different binding strengths and suitable stability characteristics. Here we show the results of the survey, the selection procedure, validation and final selection of a panel of nanobody interaction standards.

show abstract

Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications

Abstract: Camel-derived nanobodies as versatile biomaterials for biomedical applications.

Cited by 20 publications

References 95 publications

Immunotherapies and immunomodulatory approaches in clinical trials - a mini review

Immunotherapies and immunomodulatory approaches in clinical trials - a mini review

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors

Interaction standards for biophysics: anti-lysozyme nanobodies

Contact Info

Product

Resources

About